Aspiro Therapeutics Named Finalist in Flinn Foundation Bioscience Entrepreneurship Program

Tucson, AZ / March 7, 2025 – Aspiro Therapeutics, a biotechnology company developing next-generation treatments for obstructive lung diseases, has been selected as a finalist in the Flinn Foundation Bioscience Entrepreneurship Program. The program recognizes Arizona-based bioscience startups with high-impact innovations poised to improve human health.

Aspiro is focused on advancing disease-modifying therapies for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The company’s lead candidate is designed to mimic the protective power of CC16, a naturally occurring lung protein, to restore lung function and prevent disease progression.

“We are honored to be recognized as a finalist in this year’s Flinn Foundation Bioscience Entrepreneurship Program,” said James Lovgren, CEO & Co-Founder of Aspiro Therapeutics. “This recognition highlights our commitment to developing transformative respiratory therapies that move beyond symptom management and address the underlying causes of disease.”

Selection as a finalist reinforces Aspiro Therapeutics’ position as an emerging leader in respiratory drug development. The company remains committed to driving innovation in lung health and accelerating the path toward delivering breakthrough therapies to patients in need.

Read the official announcement from the Flinn Foundation here.

About the Flinn Foundation

The Flinn Foundation is a philanthropic grant-making organization dedicated to improving the quality of life in Arizona to benefit future generations. Founded in 1965, the foundation provides funding for initiatives in the fields of bioscience, health care, and education, with a mission to drive advancements that strengthen Arizona’s biomedical research ecosystem. Through its seed grant program, the Flinn Foundation supports high-potential research projects and innovators working to transform health care and improve patient outcomes.